Relay Therapeutics (RLAY) Stock Overview
Operates as a clinical-stage precision medicines company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RLAY Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Relay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.05 |
| 52 Week High | US$7.64 |
| 52 Week Low | US$1.78 |
| Beta | 1.52 |
| 1 Month Change | -6.92% |
| 3 Month Change | 80.60% |
| 1 Year Change | -1.79% |
| 3 Year Change | -69.40% |
| 5 Year Change | -87.81% |
| Change since IPO | -82.74% |
Recent News & Updates
Recent updates
Relay Therapeutics Is A Buy For Its Superb Safety Data
Oct 24Here's Why We're Watching Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Apr 12
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Feb 14We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
Dec 19Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials
Dec 01Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Sep 11Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Aug 03Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Shareholder Returns
| RLAY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.8% | -0.5% | -2.0% |
| 1Y | -1.8% | -1.1% | 12.1% |
Return vs Industry: RLAY matched the US Biotechs industry which returned -1.1% over the past year.
Return vs Market: RLAY underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| RLAY volatility | |
|---|---|
| RLAY Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RLAY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RLAY's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 188 | Sanjiv Patel | www.relaytx.com |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.
Relay Therapeutics, Inc. Fundamentals Summary
| RLAY fundamental statistics | |
|---|---|
| Market cap | US$1.05b |
| Earnings (TTM) | -US$297.59m |
| Revenue (TTM) | US$8.36m |
Is RLAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLAY income statement (TTM) | |
|---|---|
| Revenue | US$8.36m |
| Cost of Revenue | US$267.60m |
| Gross Profit | -US$259.24m |
| Other Expenses | US$38.35m |
| Earnings | -US$297.59m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | -3,102.84% |
| Net Profit Margin | -3,561.86% |
| Debt/Equity Ratio | 0% |
How did RLAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/10 09:02 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relay Therapeutics, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Gaurav Goparaju | Berenberg |